Fintech PR
KSA BNPL Revolution: Market Set to Surge 48% as Consumers Embrace Flexible Payment: Ken Research
GURUGRAM, India, Feb. 27, 2024 /PRNewswire/ — The Kingdom of Saudi Arabia Buy Now, Pay Later (BNPL) market is experiencing explosive growth, fueled by a surge in digital adoption, increasing smartphone penetration, and a flourishing e-commerce landscape. Ken Research’s comprehensive report, KSA Buy Now, Pay Later (BNPL) Market Outlook to 2028: Empowering Consumers, Reshaping Retail, delves into this dynamic market, projecting a remarkable 48% CAGR over the next five years. This press release summarizes the key findings and offers valuable insights for investors, financial institutions, retailers, and stakeholders seeking to capitalize on this flourishing ecosystem.
Market Overview:
Several key factors are propelling the KSA’s BNPL market towards a future of convenient and accessible financing:
- Digital Savvy Population: The Kingdom boasts a highly tech-savvy population with high smartphone penetration, creating fertile ground for mobile-based BNPL solutions.
- E-Commerce Boom: The booming e-commerce industry in KSA is driving the adoption of BNPL options, offering consumers convenient checkout and payment flexibility.
- Financial Inclusion: BNPL solutions cater to unbanked or underbanked populations, promoting financial inclusion and increasing access to credit.
- Government Initiatives: Vision 2030 and other government initiatives focused on financial technology (FinTech) are fostering innovation and growth in the BNPL sector.
Interested to Know More about this Report, Request a Free Sample Report
Segmentation Spotlight:
Ken Research provides a detailed segmentation of the market, allowing you to pinpoint your target audience effectively:
- By Player Type: Leading BNPL players like Tamara, Saudi Post, and Tabby hold a significant share, followed by international giants like After pay and Klarna entering the market.
- By Product Type: Point-of-sale (POS) financing dominates, followed by pure-play online BNPL solutions. Integrated BNPL solutions with e-commerce platforms are gaining traction.
- By Target Segment: Millennials and Gen Z are the primary target audiences, but adoption is increasing across all age groups. Online shoppers and individuals seeking accessible credit constitute the primary user base.
- By Merchant Category: E-commerce platforms, fashion and apparel retailers, electronics stores, and travel and entertainment sectors are the major beneficiaries of BNPL adoption.
Competitive Landscape:
The KSA’s BNPL market features a mix of established players, emerging startups, and international entrants:
- Domestic Pioneers: Homegrown BNPL players like Tamara and Saudi Post are leading the market, offering innovative solutions tailored to local needs and regulations.
- Global Players: Established international BNPL giants like after pay and Klarna are entering the market with their global expertise and advanced technologies.
- Strategic Partnerships: Partnerships between BNPL players with e-commerce platforms, banks, and retailers are fostering wider adoption and market penetration.
Visit this Link :- Request for custom report
Recent Developments:
- Regulatory Framework: The Saudi Arabian Monetary Authority (SAMA) has established a regulatory framework for BNPL providers, ensuring consumer protection and market stability.
- Open Banking Initiatives: Open banking initiatives are enabling collaboration between BNPL players and traditional financial institutions, offering a wider range of financial services.
- Focus on Financial Literacy: Initiatives are underway to educate consumers about BNPL options, promoting responsible borrowing practices and managing financial well-being.
Future Outlook:
The KSA’s BNPL market is poised for exciting developments in the coming years:
- Product Innovation: Diversification of BNPL products beyond traditional retail purchases, such as travel and healthcare financing, will be observed.
- Expansion into Emerging Segments: BNPL solutions will cater to underserved segments, including small and medium-sized enterprises (SMEs) and unbanked populations.
- Data Analytics and AI: Adoption of data analytics and artificial intelligence will enhance risk assessment, personalize offers, and provide targeted marketing strategies.
- Collaboration and Partnerships: Collaboration between BNPL players, financial institutions, and retailers will foster stronger ecosystems and enhance user experience.
Challenges to Address:
Despite its promising future, the market faces some hurdles:
- Consumer Debt Concerns: Ensuring responsible use of BNPL options and preventing over-indebtedness remains a crucial concern.
- Regulatory Landscape: Continuously updating regulations in line with market developments is crucial to maintain a balanced and competitive market environment.
- Cybersecurity Concerns: Implementing robust cybersecurity measures is essential to protect consumer data and maintain user trust.
Why This Report Matters:
This report empowers various stakeholders to navigate the KSA’s BNPL market:
- Investors: Identify lucrative investment opportunities across different segments and technologies.
- Financial institutions: Understand disruptive trends, explore potential partnerships, and adapt their services to cater to the changing financial landscape.
- Retailers: Integrate BNPL options into their offerings to attract new customers, increase basket sizes, and boost sales conversions.
- Policymakers: Develop policies that foster innovation, promote responsible lending practices, and ensure consumer protection.
- Consumers: Gain insights into the BNPL landscape, make informed decisions about using these services, and manage their finances responsibly.
Request free 30 minutes analyst call
For More Insights On Market Intelligence, Refer To The Link Below: –
Related Reports by Ken Research: –
The US Micro Lending market is expected to grow at a CAGR of 12 % from 2022 to 2028 with low-interest Rates, Ease of Access, Technological Advancements, flexible repayment schedules, and Alternative credit score models. As the market is anticipated to grow remarkably in the forecasted period thus the demand for microloans will also increase significantly.
According to Ken Research estimates, the KSA Lending Market –in 2022 at a CAGR of 50.4% owing to growing demand for financing penetration in the sector. KSA’s private consumption expenditure has risen, indicating improved living standards and reduced poverty. Demographic factors influence lending preferences, with under-24 individuals seeking credit for education and ventures, while 25-54 age group seeks loans for homes and cars.
Philippine retail deposit market has been growing steadily at a CAGR of ~10% with digital penetration and convenience banking being major growth drivers. Number of Depositors in the Philippines Banking System has been growing steadily as the financial inclusion rises and the penetration of direct accounts sharply rose. Retail deposits account for ~45% of the total value of Deposits in the Philippine Banking System; Wholesale Deposits encompass a varied type of depositors with different purposes.
Buy Now Pay Later industry in South Africa is estimated to generate a revenue of USD 1569 Million in 2027E, expanding at a CAGR of double digits in between 2022P and 2027E Increasing demand for extra credit line with less stringent KYC procedures without relying on CIBIL scores will be traction for consumers for utilization of BNPL services. Retailers as end user will witness upsurge in revenue contribution to 80% of the market share as more retailers will be coming forward to incorporate the BNPL services in their online and offline store to increase consumer base by collaborating with BNPL players.
Follow Us –
LinkedIn | Instagram | Facebook | Twitter | YouTube
Contact Us:-
Ken Research Private Limited
Ankur Gupta, Director Strategy and Growth
[email protected]
+91-9015378249
Logo: https://mma.prnewswire.com/media/1954972/Ken_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ksa-bnpl-revolution-market-set-to-surge-48-as-consumers-embrace-flexible-payment-ken-research-302072394.html
NEW YORK, Dec. 18, 2024 /PRNewswire/ — The New York Stock Exchange (NYSE) is proud to offer a new daily pre-market update and additional content directly from the iconic NYSE Trading Floor.
Access the new Daily NYSE Pre-market update and additional content here: https://www.multivu.com/nyse/9306251-en-new-york-stock-exchange-pre-market-update
DAILY NYSE PRE-MARKET UPDATE
Kristen Scholer, Senior Markets Anchor, NYSE, delivers a daily pre-market update that includes key insights into the trading day ahead leading up to the NYSE’s Opening Bell.
NYSE ORIGINAL CONTENT:
Elevate your reporting with the latest market insights and content from the NYSE, the world’s leading financial marketplace by leveraging a range of exclusive NYSE content including:
- NYSE Photo Highlights: NYSE-listed companies, Trading Floor moments, Leadership events.
- NYSE B-Roll Footage: NYSE Trading Floor, Market milestones, and Bell-ringing events.
- NYSE Original Content:
- Floor Talk: Exclusive interviews with industry trend-setters and innovators.
- Inside the ICE House Podcast: Conversations with CEO, founders, and leaders.
- Taking Stock: Go face-to-face with visionary entrepreneurs who are redefining sectors.
Video – https://mma.prnewswire.com/media/2584161/NYSE_Market_Dec_18_2024.mp4
Logo – https://mma.prnewswire.com/media/2581322/5084577/New_York_Stock_Exchange_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/nyse-content-advisory-todays-pre-market-update-december-18-2024-302335036.html
Fintech PR
Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)
BEIJING and BRIDGEWATER, N.J., Dec. 18, 2024 /PRNewswire/ — Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087.SH), is pleased to announce that the Food and Drug Administration (” FDA “) has cleared the Investigational New Drug (IND) application for GZR18 Injection to conduct a phase 2 clinical trial, a head-to-head with Tirzepatide from Eli Lilly and Company (NYSE: LLY) in the US (NCT06737042). GZR18 is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (RA) being developed by Gan & Lee Pharmaceuticals. The clinical trial indication of this application is the chronic weight management for obese or overweight patients, with or without T2DM.
According to the latest data released by the World Obesity Federation (WOF) Global Obesity Report (2024), approximately 2.2 billion adults worldwide were overweight (referring to BMI ≥ 25kg/m2) in 2020, accounting for about 42% of the total adult population. It is expected that this number will rise to 3.3 billion by 20351. Obesity can lead to a series of complications, including diabetes, cardiovascular diseases and even mental diseases such as depression. The medical expenses caused by obesity and its complications have brought a heavy medical burden to patients and society.
GZR18, as a GLP-1 receptor agonist, can delay gastric emptying by activating GLP-1 receptors expressed on the gastrointestinal tract; and enhance satiety and suppress appetite by activating GLP-1 receptors in the hypothalamus and other parts, thereby reducing the patient’s weight. GZR18 injection is the first bi–weekly GLP-1 mono-agonist formulation. Current clinical data has demonstrated weight loss effects comparable to or even better than multi-target once-weekly GLP-1 formulations, providing new insights for the future development of GLP-1 drugs. The development of the bi-weekly GZR18 injection is expected to offer more flexible treatment options for obese patients , leading to improved long-term weight management efficacy and adherence.
About GZR18
GZR18 is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (RA) being developed by Gan & Lee Pharmaceuticals. The indications currently under development are type 2 diabetes and chronic weight management for obese or overweight patients. Clinical data shows that administering GZR18 injection once a week and every two weeks can achieve good hypoglycemic or weight loss effects2.
References:
1. World Obesity Alliance 2024 World Obesity Report [EB/OL]. London: World Obesity Alliance,
2. LINONG JI, WEI CHEN, RUIHUA DONG, MINGXIA YUAN, DONG ZHAO, SHUGUANG PANG, LIYUAN ZHAO, JING ZHAO, ZHONG-RU GAN; 1858-LB: A Novel GLP-1 Analog, GZR18, Induced an 18.6% Weight Reduction in Subjects with Obesity in a Phase Ib/IIa Trial. Diabetes 14 June 2024; 73 (Supplement_1): 1858–LB. https://doi.org/10.2337/db24-1858-LB
About Gan & Lee
Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin®30), and one human insulin injection – mixed protamine human insulin injection (30R) (Similin®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine®).
In China’s 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.
In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.
Further Information:
[email protected] (Media)
[email protected] (Business Development)
[email protected] (Medical Information)
Logo – https://mma.prnewswire.com/media/2439708/Gan_Lee_Pharmaceuticals_Logo.jpg
View original content:
Project in partnership with AUO starts on January 1, 2025
MANCHESTER, England, Dec. 18, 2024 /PRNewswire/ — Smartkem (Nasdaq: SMTK), which is seeking to change the world of electronics using its disruptive organic thin-film transistors (OTFTs), has received and accepted a £900,000 (USD 1.1 million) grant from Innovate UK for its previously announced project partnership with AUO to develop a rollable, transparent microLED display. Part of the 2024 UK-Taiwan Collaborative R&D Initiative, the 2-year project will commence on January 1, 2025, with initial grant payments beginning in the first quarter of 2025.
About the 2024 UK-Taiwan Collaborative R&D Initiative
The 2024 UK-Taiwan Collaborative R&D Initiative has invested more than £10 million this year to promote bilateral industrial technology research and development cooperation. The nine award-winning projects will promote the joint development of advanced technologies in fields such as electrical information communication, biomedicine, and electromechanical by Taiwan-UK enterprises.
About Smartkem
Smartkem is seeking to reshape the world of electronics with its disruptive organic thin-film transistors (OTFTs) that have the potential to revolutionize the display industry. Smartkem’s patented TRUFLEX® liquid semiconductor polymers can be used to make a new type of transistor that can be used in a number of display technologies, including next generation microLED displays. Smartkem’s organic inks enable low temperature printing processes that are compatible with existing manufacturing infrastructure to deliver low-cost displays that outperform existing technology.
Smartkem develops its materials at its research and development facility in Manchester, UK and provides prototyping services at the Centre for Process Innovation (CPI) at Sedgefield, UK. It has a field application office in Taiwan. The company has an extensive IP portfolio including 138 granted patents across 18 patent families, 16 pending patents and 40 codified trade secrets. For more information, visit: www.Smartkem.com and follow us on LinkedIn http://www.linkedin.com/company/Smartkem-limited.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors. These statements are not historical facts but rather are based on Smartkem Inc.’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or elated expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Selena Kirkwood
Head of Communications for Smartkem
T: +44 (0) 7971 460 364
[email protected]
U.S. Investors
David Barnard, CFA
Alliance Advisors Investor Relations
T: 1 415 433 3777
[email protected]
View original content:https://www.prnewswire.co.uk/news-releases/smartkem-receives-900-000-grant-from-innovate-uk-for-advanced-microled-displays-302334970.html
-
Fintech7 days agoFintech Pulse: Your Daily Industry Brief (IBANera, FIS, Citigroup, Gen Digital, Mynt)
-
Fintech6 days agoFintech Pulse: Your Daily Industry Brief (Nuvei, Google, Upvest, Gen Digital, MoneyLion)
-
Fintech PR5 days agoCathay Financial Holdings Calls for Climate Finance Mobilization to Drive the Climate Industrial Revolution
-
Fintech PR5 days agoA New Era of $WUSD — Revolutionizing Stablecoins with Unmatched Security, Stability and Next-Gen Innovation
-
Fintech2 days agoFintech Pulse: Your Daily Industry Brief (Synapse, Shenzhen Institute, Visa, AutomatIQ, MeridianLink)
-
Fintech PR5 days agoLanistar launches new gaming sites in Brazil as secures right to operate pending final approval on its licence
-
Fintech PR5 days agoHealthcare Revenue Cycle Management (RCM) Market Surges to USD 658.7 Billion by 2030, Propelled by 24% CAGR – Verified Market Reports®
-
Fintech PR5 days agoInternational Communication Forum: Pathways To A Sustainable Future